|
|||||
|
|
The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials |
|
| Authors: | Geert Molenberghs Tomasz Burzykowski Ariel Alonso Pryseley Assam Abel Tilahun Marc Buyse |
| Institution: | 1. Hasselt University, Center for Statistics, Diepenbeek, Belgium;2. International Drug Development Institute, Ottignies Louvain-la-Neuve, Belgium |
| Abstract: | For a number of reasons, surrogate endpoints are considered instead of the so-called true endpoint in clinical studies, especially when such endpoints can be measured earlier, and/or with less burden for patient and experimenter. Surrogate endpoints may occur more frequently than their standard counterparts. For these reasons, it is not surprising that the use of surrogate endpoints in clinical practice is increasing. |
| Keywords: | Hierarchical model Likelihood reduction factor Meta-analysis Random-effects model Surrogate endpoint Surrogate threshold effect |
| 本文献已被 ScienceDirect 等数据库收录！ | |